The Role of Clinical Trial Translators in Driving Global Inclusion in Decentralized Clinical Trials

First introduced 15 years ago and accelerated by the COVID-19 pandemic, Decentralized Clinical Trials (DCTs) became a focal point in 2020 and 2021—initially out of necessity but with immense potential to transform patient access, enrollment, trial efficiency, data quality, and population diversity.

The global DCT market, valued at $8.5 billion in 2023, is expected to reach $13.3 billion by 2030, growing at a compound annual rate of 6.6%, showing the increasing adoption of decentralized models and the industry’s commitment to improving. trial accessibility. However, while technology plays a vital role in enabling DCTs, it alone cannot guarantee truly global participation.

The key to their success lies in one critical factor: clear, accurate communication across languages and cultures. This is where clinical trial translators and language service providers who specialize in clinical trials play an essential role. In this article, we explore why their expertise is indispensable in making DCTs truly inclusive and effective worldwide

The Critical Role of Expert Translators in Bridging Language Gaps in Decentralized Clinical Trials

For DCTs to be truly effective, every participant—regardless of location, language, or background—must fully understand the trial they are taking part in. Unlike traditional clinical trials, which are often conducted in centralized locations with on-site staff to guide participants, DCTs rely heavily on remote engagement. This makes clear, accurate, and culturally appropriate communication even more important.

To maintain inclusivity and compliance, expert clinical trial translators and language service providers play a critical role in facilitating: 

• Multilingual informed consent forms – Participants must be able to provide truly informed consent, which means understanding the risks, benefits, and procedures of the trial in their native language. Poorly translated consent forms can lead to misunderstandings, ethical concerns, and even noncompliance with regulatory requirements.
• Accurate regulatory translations – Each country has its own regulatory requirements for clinical trials, and meeting these standards is crucial for approval and compliance. High-quality translations of trial protocols, safety documentation, and regulatory filings ensure that DCTs adhere to local laws and guidelines, avoiding costly delays and legal hurdles.
• Effective communication between researchers, trial sites, and participants – In a decentralized model, patients may communicate with trial coordinators through digital platforms, telemedicine, or mobile applications. Translators and localization experts help ensure that study instructions, progress updates, and medical guidance are clear, culturally appropriate, and easy to follow.

Why Translation Quality is Non-Negotiable in DCTs

Without expert translation and localization, the benefits of DCTs cannot be fully realized. Even minor errors in medical terminology, cultural references, or linguistic nuances can have serious consequences, including: 

• Regulatory setbacks – If documentation does not meet local regulatory requirements due to translation errors, trials can face costly delays or rejection.
• Trial delays and recruitment challenges – Poorly translated materials may confuse or deter participants, reducing engagement and slowing down enrollment.
• Patient safety risks – Miscommunication in instructions, dosage guidelines, or adverse event reporting could compromise patient well-being and trial integrity.

As decentralized trials continue to expand across diverse global populations, the demand for precise, culturally sensitive, and compliant translations will only grow. By integrating expert clinical trial translators from the outset, sponsors and researchers can ensure that their trials are not only inclusive but also meet the highest standards of accuracy, safety, and ethical responsibility.

In a world where healthcare innovation is increasingly borderless, effective communication is the key to ensuring that every patient, regardless of language or location, has the opportunity to participate in groundbreaking research that shapes the future of medicine.

How DTS Language Services Ensures Compliance and Clarity in Global Clinical Trials

DTS Language Services is a trusted partner for clinical trial sponsors, providing expert language solutions that ensure clear, precise, and compliant communication across international trials. As the clinical research landscape evolves, particularly with the rise of DCTs, the need for high-quality translations has never been greater. With over 50 years of experience and ISO certification, DTS delivers translations that meet the rigorous demands of the pharmaceutical, biotechnology, and medical research industries.

Our team of specialized linguists is not only fluent in a broad range of languages—covering Spanish, Mandarin, French, Arabic, and many more—but also possesses in-depth knowledge of life sciences and regulatory requirements. This combination of linguistic proficiency and subject matter expertise means you can be confident that every translation is both technically accurate and contextually appropriate.

By choosing DTS as your language service provider, you ensure that every participant, researcher, and regulatory body receives clear, accurate, and culturally appropriate communication—paving the way for inclusive, efficient, and successful clinical research.